Novo Nordisk shares fell after it revealed weaker-than-expected data from trials of its obesity drug candidate CagriSema, which was expected to be a worthy successor of its blockbuster obesity drug Wegovy https://t.co/SKRN5jjYKy pic.twitter.com/EZEagB2lZ0
— Reuters (@Reuters) March 11, 2025
